Market Research

Psychedelic Invest is your source for the latest business and investing news about the burgeoning psychedelics industry.

Psilocybin’s Impact on Brain Activity

Jul 23 • 3 min read

Psilocybin, the primary psychoactive compound found in hallucinogenic mushrooms, has long intrigued scientists and enthusiasts alike for its profound effects on perception and consciousness. Recent research conducted by the Washington University School of Medicine in St. Louis sheds new light on how this compound impacts the brain, offering promising insights into its potential therapeutic uses….

Therapeutic Potential of Psychedelics for Older Adults

Jul 22 • 3 min read

Psychedelics such as DMT, LSD, and psilocybin have shown significant potential in treating affective symptoms across a variety of disorders. These substances induce altered states of consciousness characterized by intensified perceptions and emotions, which are linked to therapeutic benefits. However, the inclusion of older individuals in psychedelic studies has been limited, leaving questions about the…

Psilocybin Offers Promising Relief for Cluster Headaches

Jul 16 • 4 min read

Cluster headaches are a debilitating type of headache characterized by excruciating pain, often localized to one side of the head or behind one eye. These headaches can last from 15 minutes to three hours, striking suddenly and frequently recurring multiple times a day. The intensity of the pain experienced during cluster headaches is often severe…

Braxia Scientific Corp. Delays Financial Report Amid Management Changes

Jul 16 • 2 min read

Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) recently informed its investors that it will not be able to file its audited annual consolidated financial statements for the fiscal year ending March 31, 2024, by the deadline of July 31, 2024. This delay also extends to the related management’s discussion and analysis, as well as…

Oregon’s Psilocybin Industry: A Year of Growth and Challenges

Jul 11 • 7 min read

The psilocybin industry in Oregon has reached a significant milestone: its first anniversary. This burgeoning sector, born out of Measure 109, which legalized the supervised use of psilocybin for mental health treatment, has seen both triumphs and trials. As the state continues to pioneer this new frontier in psychedelic therapy, stakeholders are reflecting on the…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354